Efficacy assessment of UVA1 and narrowband UVB for treatment of scalp psoriasis

Lasers Med Sci. 2018 Dec;33(9):1979-1982. doi: 10.1007/s10103-018-2564-z. Epub 2018 Jun 18.


To compare the efficacy and safety of UVA1 and narrowband UVB (NB-UVB) therapy in the treatment of scalp psoriasis. Patients with scalp psoriasis were randomly assigned to either UVA1 or NB-UVB therapy. Both treatments were performed three times weekly for 6 weeks. Clinical efficacy was evaluated by using Psoriasis Scalp Severity Index (PSSI), and patient-reported quality of life (QoL) was assessed by Dermatology Life Quality Index (DLQI). Totally 68 patients completed the study. Both UVA1 and NB-UVB phototherapy achieved a statistically significant reduction of PSSI and DLQI scores at the end of the treatment period. Compared with the NB-UVB group, the significantly greater improvements occurred in UVA1 treatment group at week 3, although differences declined thereafter through week 10. Both UVA1 and NB-UVB therapy were well-tolerated in this study, and the occurrence of adverse events (AEs) was uncommon. Both UVA1 and NB-UVB phototherapy could offer relief of scalp symptoms in patients with scalp involvement. Furthermore, UVA1 treatment could improve the clinical manifestations and QoL more quickly than NB-UVB therapy.

Keywords: Narrowband UVB; Psoriasis; Scalp; UVA1.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Female
  • Humans
  • Male
  • Middle Aged
  • Psoriasis / radiotherapy*
  • Quality of Life
  • Scalp / pathology*
  • Scalp / radiation effects*
  • Treatment Outcome
  • Ultraviolet Therapy* / adverse effects
  • Young Adult